Dianthus Therapeutics, Inc. (DNTH) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Dianthus Therapeutics reported revenue of $2.0M, down 67.3% from $6.2M the year before. Net income was -$162.3M (a -7973.3% net margin), or -$4.20 per diluted share. Operating margin was -8739.3%. Operating activities generated -$129.1M of cash. At fiscal year end, Dianthus Therapeutics held $530.9M in total assets against $37.5M in total liabilities, including $51.1M of cash and equivalents.
Open the full interactive Dianthus Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Dianthus Therapeutics Key Stats
| Share Price | $77.58 |
|---|---|
| Market Cap | $4.35B |
| Revenue YoY Growth | -67.3% |
| 52-Week Range | $32.92 – $115.96 |
| Shares Outstanding | 56.0 million (basic, 2026 Q2) |
Dianthus Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $6.2M | $2.0M |
| Operating Income | -$78.7M | -$74.7M | -$80.9M | -$48.2M | -$101.9M | -$177.9M |
| Pre-Tax Income | -$74.9M | -$71.1M | -$76.5M | -$43.6M | -$85.0M | -$162.3M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$74.9M | -$71.1M | -$76.5M | -$43.6M | -$85.0M | -$162.3M |
| Diluted EPS | -$1.71 | -$1.29 | -$1.29 | -$8.45 | -$2.55 | -$4.20 |
Dianthus Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $396,000 | $284,000 | $0 | $0 |
| Net Income | -$36.8M | -$64.4M | -$40.8M | -$50.2M |
| Diluted EPS | -$0.97 | -$1.67 | -$0.85 | -$0.90 |
Dianthus Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $58.2M | $131.7M | $57.6M | $132.3M | $22.8M | $51.1M |
| Current Assets | $151.5M | $180.7M | $115.6M | $177.5M | $280.9M | $409.4M |
| Total Assets | $161.6M | $189.9M | $146.6M | $179.4M | $374.0M | $530.9M |
| Current Liabilities | $11.4M | $10.9M | $14.5M | $9.6M | $18.5M | $30.7M |
| Total Liabilities | $17.7M | $17.3M | $40.7M | $10.5M | $21.5M | $37.5M |
| Shareholders' Equity | $143.9M | $172.7M | $106.0M | $168.9M | $352.5M | $493.4M |
Dianthus Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$64.0M | -$59.5M | -$67.1M | -$36.9M | -$78.2M | -$129.1M |
| Cash From Investing | -$10.6M | $43.4M | -$9.8M | $20.3M | -$286.8M | -$122.8M |
| Cash From Financing | $67.7M | $89.6M | $2.9M | $133.6M | $255.6M | $280.1M |
| Free Cash Flow | -$64.4M | -$60.8M | -$67.4M | — | — | — |
Figures from Dianthus Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Dianthus Therapeutics financials page for every line item.
Dianthus Therapeutics Company Profile
| Ticker | DNTH |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001690585 |
Frequently Asked Questions
What was Dianthus Therapeutics' revenue in fiscal 2025?
Dianthus Therapeutics (DNTH) reported revenue of $2.0M for fiscal 2025.
What is Dianthus Therapeutics' annual revenue history?
Dianthus Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $6.2M; 2025: $2.0M.
What was Dianthus Therapeutics' net income in fiscal 2025?
Dianthus Therapeutics reported net income of -$162.3M for fiscal 2025.
What was Dianthus Therapeutics' earnings per share (EPS) in fiscal 2025?
Dianthus Therapeutics' diluted EPS was -$4.20 for fiscal 2025 (adjusted for any later stock splits).
What was Dianthus Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Dianthus Therapeutics reported revenue of $0.
How many shares of Dianthus Therapeutics are outstanding?
Dianthus Therapeutics reported a weighted average of 56.0 million basic shares outstanding in 2026 Q2.
What is Dianthus Therapeutics' market cap?
Based on its latest closing price, Dianthus Therapeutics (DNTH) has a market capitalization of about $4.35B.
When does Dianthus Therapeutics' fiscal year end?
Dianthus Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Dianthus Therapeutics headquartered?
Dianthus Therapeutics lists its business address in New York, New York in its SEC filings.